The treatment landscape for unresectable or metastatic melanoma continues to expand. Combination checkpoint inhibitor regimens are established first-line treatment options, and BRAF/MEK-targeted therapy continues to play a role for patients with BRAF V600-mutated disease.1,2 Despite this progress, many patients still do not achieve durable disease control with currently approved therapies.2,3
Cellular therapies, including tumor-infiltrating lymphocyte (TIL) products such as lifileucel, represent one option for patients who progress after anti-PD-1 therapy (and BRAF-targeted therapy, when applicable).4 Other engineered T-cell approaches are also in development, with additional cellular therapy platforms currently undergoing phase III evaluation.5 TIL therapy in particular requires a multi-step process, including tumor tissue procurement, weeks of ex vivo manufacturing, lymphodepleting chemotherapy, cell infusion, and IL-2 support, coordinated through a specialized treatment center.6,7
Because of this extended timeline, early evaluation may help maximize the opportunity for eligible patients to pursue cellular therapy while they remain well positioned to complete the full treatment course. Some clinicians favor initiating the evaluation process as soon as disease progression is identified, often by the community oncologist managing the patient’s ongoing care, even while other options remain under consideration, rather than waiting until later lines of therapy. Evidence supporting this approach includes a single-center retrospective study, which found that patients referred later in their disease course were less likely to ultimately receive treatment, most often due to disease progression, comorbidities, or eligibility criteria identified after referral, suggesting that earlier engagement with a specialized center may help preserve treatment options for appropriate candidates.6
Community physicians and other referring clinicians are often the first to recognize disease progression and are therefore well positioned to identify candidates for cellular therapy early in the treatment course. Initiating a conversation with a specialized treatment center at the time progression is identified, rather than after other options have been exhausted, allows eligibility to be assessed while performance status and organ function remain favorable.6 As the field of cellular and other emerging therapies continues to mature, further evidence is needed to clarify optimal timing and sequencing across the expanding range of options available to patients with advanced melanoma.
Take our metastatic melanoma quiz to see how your knowledge compares to your peers.
